✦ LIBER ✦

Xanomeline, a potent and specific M1 agonist in the treatment of mild and moderate Alzheimer's disease

✍ Scribed by Pretzsch, Hans

Book ID: 124116372
Publisher: Elsevier Science
Year: 1994
Tongue: English
Weight: 123 KB
Volume: 15
Category: Article
ISSN: 0197-4580
DOI: 10.1016/0197-4580(94)93060-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

SAT-5-3 Xanomeline in mild and moderate

SAT-5-3 Xanomeline in mild and moderate Alzheimer's disease; the effects of a novel M1 agonist on behavior

✍ Neil C. Bodick; Walter Offen 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 278 KB

S-16-4 Xanomeline: The first study of th

S-16-4 Xanomeline: The first study of the safety and efficacy of an M1 agonist in mild and moderate Alzheimer's disease

✍ Neil C. Bodick; Walter Offen 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 143 KB

The safety and tolerance of Xanomeline t

The safety and tolerance of Xanomeline tartrate an M1-specific cholinergic agonist, in patients with Alzheimer's disease

✍ Cutler, NR; Sramek, JJ; Seifert, RD; Conrad, JJ; Wardle, TS; Dies, F; Hurley, DJ 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 173 KB

Xanomeline: A selective muscarinic agoni

Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease

✍ Frank P. Bymaster; Celia A. Whitesitt; Harlan E. Shannon; Neil DeLapp; John S. W 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 3 views

Xanomeline is a novel muscarinic receptor agonist relatively devoid of parasympathomimetic side effects. Xanomeline had high affinity for muscarinic receptors and much lower affinity for a variety of other neuronal receptors in radioligand binding assays. Functional studies in cell lines transfected

41-5 - Transdermal delivery of xanomelin

41-5 - Transdermal delivery of xanomeline, and M1/M4 agonist in development for the treatment of Alzheimer's disease

✍ N.C. Bodick; R. Lucas; J.H. Satterwhite; W.W. Offen 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 429 KB

SAT-5-2 The discovery and pharmacology o

SAT-5-2 The discovery and pharmacology of xanomeline, a muscarinic M1 receptor agonist for Alzheimer's disease

✍ H.E. Shannon; E.P. Bymaster; D.O. Calligaro; N.W. DeLapp; C.H. Mitch; J.S. Warc; 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 138 KB